Hemostemix Inc. (CVE:HEM – Get Free Report) shares shot up 25% during trading on Thursday . The stock traded as high as C$0.36 and last traded at C$0.35. 1,444,856 shares changed hands during trading, an increase of 111% from the average session volume of 684,559 shares. The stock had previously closed at C$0.28.
Hemostemix Stock Up 7.1 %
The firm has a market capitalization of C$32.67 million, a P/E ratio of -18.75 and a beta of 0.20. The firm has a 50 day moving average of C$0.13 and a 200-day moving average of C$0.09.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Bloom Energy: Powering the Future With Decentralized Energy
- Do ETFs Pay Dividends? What You Need to Know
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
